相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Molecular mechanisms and physiological functions of mitophagy
Mashun Onishi et al.
EMBO JOURNAL (2021)
Nuclear sensing of breaks in mitochondrial DNA enhances immune surveillance
Marco Tigano et al.
NATURE (2021)
A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer
A. S. Fung et al.
LUNG CANCER (2021)
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial
Patrizia Froesch et al.
LUNG CANCER (2021)
Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma
Robin Reschke et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Mitochondrial DNA in inflammation and immunity
Joel S. Riley et al.
EMBO REPORTS (2020)
Mechanisms of selective autophagy and mitophagy: Implications for neurodegenerative diseases
Charleen T. Chu
NEUROBIOLOGY OF DISEASE (2019)
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
Laura M. McLane et al.
Annual Review of Immunology (2019)
Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis
Andrew M. Frederickson et al.
IMMUNOTHERAPY (2019)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West et al.
LANCET ONCOLOGY (2019)
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
Cathy Eng et al.
LANCET ONCOLOGY (2019)
Intestinal infection triggers Parkinson's disease-like symptoms in Pink1-/- mice
Diana Matheoud et al.
NATURE (2019)
The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy
David A. Schaer et al.
CLINICAL CANCER RESEARCH (2019)
Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy
Diego Chowell et al.
NATURE MEDICINE (2019)
Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells
Markus Kleih et al.
CELL DEATH & DISEASE (2019)
Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages
Emeric Limagne et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Defining 'T cell exhaustion'
Christian U. Blank et al.
NATURE REVIEWS IMMUNOLOGY (2019)
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel et al.
NATURE REVIEWS CANCER (2019)
The sensing of mitochondrial DAMPs by non-immune cells
Aida Rodriguez-Nuevo et al.
CELL STRESS (2019)
A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma
Brett W. Stringer et al.
SCIENTIFIC REPORTS (2019)
Mitophagy in Intestinal Epithelial Cells Triggers Adaptive Immunity during Tumorigenesis
Paul K. Ziegler et al.
CELL (2018)
Mitophagy and Quality Control Mechanisms in Mitochondrial Maintenance
Sarah Pickles et al.
CURRENT BIOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Role of Optineurin in the Mitochondrial Dysfunction: Potential implications in Neurodegenerative Diseases and Cancer
Robert Weil et al.
FRONTIERS IN IMMUNOLOGY (2018)
Parkin and PINK1 mitigate STING-induced inflammation
Danielle A. Sliter et al.
NATURE (2018)
Demonstration of Mitochondrial Damage and Mitophagy in Cisplatin-Mediated Nephrotoxicity
Miki Ichinomiya et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE (2018)
Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy
Jean-David Fumet et al.
BRITISH JOURNAL OF CANCER (2018)
Exploring the Role of Autophagy-Related Gene 5 (ATG5) Yields Important Insights Into Autophagy in Autoimmune/Autoinflammatory Diseases
Xin Ye et al.
FRONTIERS IN IMMUNOLOGY (2018)
Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value
Giulia Mazzaschi et al.
CLINICAL CANCER RESEARCH (2018)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
A fluorescence-based imaging method to measure in vitro and in vivo mitophagy using mt-Keima
Nuo Sun et al.
NATURE PROTOCOLS (2017)
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis
Alexandra Snyder et al.
PLOS MEDICINE (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
Intratumoral (i.t.) IMO-2125 (IMO), a TLR9 agonist, in combination with ipilimumab (ipi) in PD-(L)1 refractory melanoma (RM)
Marc Isamu Uemura et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Immunogenic cell death in cancer and infectious disease
Lorenzo Galluzzi et al.
NATURE REVIEWS IMMUNOLOGY (2017)
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Peter J. R. Ebert et al.
IMMUNITY (2016)
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Christina Pfirschke et al.
IMMUNITY (2016)
In situ vaccination for the treatment of cancer
Linda Hammerich et al.
IMMUNOTHERAPY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The MEK inhibitor trametinib separates murine graft-versus-host disease from graft-versus-tumor effects
Hidekazu Itamura et al.
JCI INSIGHT (2016)
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
L. Apetoh et al.
ANNALS OF ONCOLOGY (2015)
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W. L. Teng et al.
CANCER RESEARCH (2015)
Oxaliplatin-Based Doublets Versus Cisplatin or Carboplatin-Based Doublets in the First-Line Treatment of Advanced Nonsmall Cell Lung Cancer
Jing Yu et al.
MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pemetrexed induces apoptosis in malignant mesothelioma and lung cancer cells through activation of reactive oxygen species and inhibition of sirtuin 1
Ki-Eun Hwang et al.
ONCOLOGY REPORTS (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Antonella Sistigu et al.
NATURE MEDICINE (2014)
Genetic Screens in Human Cells Using the CRISPR-Cas9 System
Tim Wang et al.
SCIENCE (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
Immunogenic Cell Death in Cancer Therapy
Guido Kroemer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Guangchuang Yu et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2012)
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors
Francois Ghiringhelli et al.
NATURE MEDICINE (2009)
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
NATURE MEDICINE (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
分享论文
